drugset / Trial / NCT05715944
Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2
Phase 3
Completed
10888 enrolled
Botswana Harvard AIDS Institute Partnership
AstraZeneca · collabBotswana Ministry of Health · collab
NaSingle-groupOpen-labelPrevention
Summary
The AstraZeneca Study is a single-arm, open-label, interventional, Phase 3b study to determine the incidence of laboratory-confirmed COVID-19 hospitalizations, disease severity, and deaths and attributable adverse events (AEs) in participants in Botswana given 1 to 2 injections of AZD1222 eight to twelve weeks apart as primary series and/or 1 injection as booster dose. Length of follow-up will be 6 to 12 months, depending upon at which dose a participant is enrolled.
Timeline
- Start
- 2021-09-15
- Primary completion
- 2022-12-30
- Completion
- 2022-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD1222 | Vaccine | — | — |